Introduction {#s1}
============

Icariin (C~33~H~40~O~15~, molecular weight = 676.7), the chemical structure of which has been reported by Tao et al. ([@B32]), is a flavonoid monomer extracted from *Herba Epimedii*. It has been confirmed to have a variety of pharmacological and biological effects, including anti-inflammatory (Xu et al., [@B41]; Tao et al., [@B32]), antioxidant (Liu et al., [@B17]; Huang et al., [@B11]), anti-tumor (Wang et al., [@B38]; Tan et al., [@B30]), and neuroprotective effects (Liu et al., [@B16]). It was recently reported that icariin protected H9c2 cells from apoptosis by inhibiting endoplasmic reticular stress and the reactive oxygen species-dependent JNK and p38 pathways (Zhang et al., [@B43]; Zhou et al., [@B44]). Icariin was also found to ameliorate cardiac remodeling and left ventricular dysfunction in rats with heart failure by attenuating matrix metalloproteinase activity and myocardial apoptosis (Song et al., [@B28]). Furthermore, icariin protected the heart from ischemia-reperfusion injury through PI3K-Akt signaling pathway activation (Ke et al., [@B12]). Additionally, Sun et al. ([@B29]) found that icariin facilitated the differentiation of mouse embryonic cells into cardiomyocytes. The results of these studies indicate that icariin has cardioprotective effects. However, the effects of icariin on APs and ion channels in cardiomyocytes have not been reported. Thus, the aim of the present study was to investigate the effects of icariin on action potentials (APs), ion currents in cardiomyocytes, as well as arrhythmias in whole rabbits, and to further investigate the medicinal value of icariin for the treatment of heart diseases.

Materials and methods {#s2}
=====================

Cardiomyocyte isolation
-----------------------

The animal experiments performed in this investigation conformed to the Guide for Care and Use of Laboratory Animals of Hubei Province, China, and the study protocol was approved by Experimental Animal Ethics Committee of Wuhan University of Science and Technology. Hearts from adult New Zealand white rabbits (1.5--2 kg) of either sex were quickly removed and retrogradely perfused by the Langendorff method, as described previously (Wu, [@B39]), with Ca^2+^-free Tyrode solution containing the following compounds (in mM): 135 NaCl, 5.4 KCl, 1.0 MgCl~2~, 10 glucose, 0.33 NaH~2~PO~4~, and 10 HEPES, pH 7.4 with NaOH for 5 min. Then, hearts were perfused with Ca^2+^-free Tyrode solution containing collagenase type I (1 g/l) and bovine serum albumin (BSA, 1 g/l) for 30--40 min before being perfused with KB solution for another 5 min. After perfusion, the left ventricle and left atrium were isolated and gently agitated in KB solution. The cardiomyocytes were filtered through a nylon mesh and stored in KB solution containing the following compounds (in mM): 70 KOH, 40 KCl, 20 KH~2~PO4, 50 glutamic acid, 20 taurine, 0.5 EGTA, 10 glucose, 10 HEPES, and 3.0 MgSO4, pH 7.4 with KOH. All solutions used in this study were saturated with 95% O~2~ and 5% CO~2~ and were maintained at 37°C.

AP recordings
-------------

For AP recording, quiescent and Ca^2+^-tolerant cardiomyocytes were bathed in standard Tyrode solution. The patch pipette solution contained the following reagents (in mM): 110 K-aspartate, 30 KCl, 5 NaCl, 10 HEPES, 0.1 EGTA, 5 MgATP, 5.0 creatine phosphate, and 0.05 CAMP, pH 7.2 with KOH. When filled with pipette solution, the electrode resistance was in the range of 1.5--2.5 MΩ. APs were induced in current-clamp mode by 1.5-fold diastolic threshold current pulses of 5 ms in duration at different pacing cycle lengths (CLs).

Ion current recordings
----------------------

Currents were recorded with a patch-clamp amplifier (EPC9, Heka electronic, Lambrecht, Pfalz, Germany) and were filtered at 2 kHz and digitized at 10 kHz.

The bath solution used for I~NaT~ recording contained the following compounds (in mM): 30 NaCl, 1.0 CaCl~2~, 105 CsCl, 1.0 MgCl~2~, 0.05 CdCl, 5.0 HEPES, and 5.0 glucose, pH 7.4 with CsOH, and 1 μM nicardipine was added to the bath solution to block I~CaL~. The pipette solution contained the following compounds (in mM): 120 CsCl, 1.0 CaCl~2~, 5.0 MgCl~2~, 5.0 Na~2~ATP, 10 TEA-Cl, 11 EGTA, and 10 HEPES, pH 7.3 with CsOH. I~NaT~ was determined by 300-ms depolarization pulses from −70 mV to +40 mV in 5-mV increments---using a holding potential (HP) of −90 mV---at 0.5 Hz. For the steady-state inactivation protocols, currents were recorded using 100-ms conditional prepulses from −100 mV to −50 mV in 5 mV increments---using a HP of −90 mV---followed by a 100-ms test pulse at −20 mV and 0.5 Hz.

The bath solution used for I~NaL~ recording contained the following compounds (in mM): 135 NaCl, 5.4 CsCl, 1.0 MgCl~2~, 10 glucose, 0.33 NaH~2~PO~4~, 0.3 BaCl~2~, 10 HEPES, and 1.8 CaCl~2~, pH 7.4 with NaOH, and 1 μM nicardipine was added to the bath solution to block I~CaL~. The pipette solution used for this experiment was the same as that used for I~NaT~ recording I~NaL~ was recorded using a 300-ms depolarization pulse at a HP of −90 mV, followed by pulses with potentials that were increased from −80 mV to +60 mV in 10-mV increments, and was measured at 200 ms in depolarization testing pulse.

The bath solution (except nicardipine) used for I~CaL~ recording was the same as that used for I~NaL~ recording. The electrode was filled with an internal solution containing the following compounds (in mM): 80 CsCl, 60 CsOH, 40 aspartate acid, 0.65 CaCl~2~,5.0 HEPES, 10 EGTA, 5.0 MgATP, and 5.0 Na~2~-creatine phosphate, pH 7.2 with CsOH. I~CaL~ was determined using 300-ms voltage steps with potentials that were increased from −40 mV to +50 mV in 5-mV increments at 0.5 Hz. For the steady-state inactivation protocol, I~CaL~ was determined using 2,000-ms conditional prepulses with potentials that were increased from −50 mV to 0 mV in 5-mV increments---using a HP of −40 mV---followed by a 300-ms test pulse at 0 mV.

For I~K1~ recording, the cells were bathed with Tyrode solution, and 1 μM nicardipine was used to block I~CaL~. The internal solution contained the following compounds (in mM): 140 KCl, 1.0 MgCl~2~, 5.0 K~2~ATP, 10 EGTA, and 5.0 HEPES, pH 7.3 with KOH.

The external solution used to record I~Kr~ contained the following compounds (in mM): 135 NaCl5.4 KCl, 1.0 MgCl~2~, 5.0 glucose, 0.2 CdCl~2~, 0.33 NaH~2~PO~4~, 5.0 HEPES, and 1.0 CaCl~2~, pH 7.4 with NaOH, and 30 μM chromanol 293B was used to block I~Ks~. The pipette solution contained the following compounds (in mM): 140 KCl, 1.0 MgCl~2~, 2.0 Na~2~ATP, 10 EGTA, and 5.0 HEPES, pH 7.25 with KOH.

The bath solution used to elicit I~to~ contained the following compounds (in mM): 140 NaCl, 5.4 KCl, 1.0 MgCl~2~, 10 glucose, 0.33 NaH~2~PO~4~, 5 HEPES, and 1.8 CaCl~2~, pH 7.4 with NaOH. The internal solution contained the following compounds (in mM): 110 K-aspartate, 20 KCl, 0.1 GTP, 1.0 MgCl~2~, 10 HEPES, 5.0 EGTA, 5.0 MgATP, and 5.0 creatine phosphate, pH 7.2 with KOH. BaCl~2~(200 μM), CdCl~2~ (200 μM), and atropine (1 μM) were used to block I~K1~, I~CaL~, and I~KAch~, respectively.

The bath solution and pipette solution used to record I~Kur~ were the same as those used to record I~to~, but the pulse protocol was different from that used to record I~to~ (see the Results Section).

Aconitine-induced arrhythmias in whole rabbits
----------------------------------------------

Twenty healthy New Zealand rabbits were randomly divided into two groups (*n* = 10 for each group): normal saline (NS) and icariin. In the NS group, saline was injected intraperitoneally within half an hour before the experiment. In the icariin group, 3 mg/kg icariin was injected intraperitoneally within half an hour before the experiment. At the beginning of the experiments, both groups of rabbits were anesthetized with xylazine (7.5 mg/kg, i.m.) and ketamine (30 mg/kg, i.v.) through ear vein injection. A standard limb lead II electrocardiogram (ECG) was recorded using the BL-420F data acquisition and analysis system (Chengdu TaiMeng, Sichuan, China) for 120 min following the application of 2 μg/kg/min aconitine, which was injected by a constant velocity pump and used to induce arrhythmias. The onset time and onset dosage of aconitine that induced ventricular premature contraction (VPC), ventricular tachycardia (VT) and ventricular fibrillation (VF) were measured.

Drugs and reagents
------------------

Icariin (purity \>97%) was obtained from Sigma Aldrich (Saint Louis, MO, USA). Collagenase type I and CsCl were purchased from Gibco (GIBCO TM, Invitrogen Co., Paisley, UK). BSA and HEPES were obtained from Roche (Basel, Switzerland), and the other chemicals were obtained from Sigma Aldrich (Saint Louis, MO, USA). Dimethyl sulfoxide (DMSO) was used to dissolve icariin to obtain a 1 mM stock solution. The final concentration of the DMSO added to the bath solution was less than 0.1%.

Data analysis
-------------

Fitmaster (v2x32, HEKA) was used for data analysis, and the figures were plotted by Origin 8.0 (OriginLab Co., MA, USA). All data were expressed as the mean ± SD. Data pertaining to the I~NaT~ and I~CaL~ steady-state activation and steady-state inactivation relationships were fitted by the Boltzmann equation, *Y* = 1/{1+exp (*V*~*m*~−*V*~1/2~)/*k*}, where *V*~*m*~ is the membrane potential, *V*~1/2~ is the half-activation and half-inactivation potential, *k* is the slope factor, and *Y* is relative conductance (*G/G*~*max*~, steady-state activation) and relative current (*I/I*~*max*~, steady-state inactivation). The dose-response relationship curves for the effects of icariin on I~NaT~ and I~CaL~ were fitted to the Hill equation, (*I*~*control*~−*I*~*drug*~)/*I*~*drug*~ = *E*~*max*~/\[1 + (*IC*~50~*/C*)^*n*^\], where *I*~*control*~ and *I*~*drug*~ represent the amplitude of I~NaT~ and I~CaL~ obtained in the absence and presence of icariin, respectively, *E*~*max*~ is the maximum inhibition, *IC*~50~ is the concentration of icariin at which its half-maximum inhibitory effects are exerted, *C* is the concentration of icariin, and *n* is the Hill coefficient. Current density was calculated by dividing the current amplitude by the cell capacitance. The statistical significance of the differences between two groups was determined by Student\'s *t*-test, and mean comparisons among multiple groups were performed by one-way analysis of variance (ANOVA) followed by Bonferroni\'s test. *P* \< 0.05 was considered significant.

Results {#s3}
=======

Figure [1A](#F1){ref-type="fig"} shows the representative morphologies of a single isolated left ventricular myocyte (LVM, left) and left atrial myocyte (LAM, right). The rod-shaped LVM had glossy and smooth edges, as well as the typical transverse striations. The LAM was more slender than the LVM.

![**Icariin attenuated APDs in a concentration- and rate-dependent manner in rabbit LVMs and LAMs. (A)**. Photomicrograph of a single LVM (left) and LAM (right). **(B)**. Effects of icariin (5 and 10 μM) on APs elicited at a stimulation frequency of 1 Hz in LVMs (left) and LAMs (right). **(C)**. Representative recordings of APs elicited at 0.5 Hz, 1 Hz and 2 Hz in the absence and presence of icariin (5 and 10 μM) in ventricular myocytes. **(D)**. Data pertaining to APD~90~ from 30 sequential curves were averaged. The averaged data for different pacing CLs are shown, *n* = 9 cells/4 rabbits. ^&^ and ^&&^*p* \< 0.05 and 0.01 vs. a pacing CL of 500 ms; ^\*\*^ *p* \< 0.01 vs. control at the same pacing CL; ^\#\#^*p* \< 0.01 vs. 5 μM icariin at the same pacing CL.](fphys-08-00342-g0001){#F1}

Effects of icariin on action potentials
---------------------------------------

APs were consecutively recorded by 5-ms and 1.5-fold threshold current pulses at 1 Hz in the absence and presence of icariin. Icariin attenuated AP amplitude (APA) and the maximum upstroke velocity (V~max~), shortened action potential durations (APDs) at 50 and 90% repolarization (APD~50~ and APD~90~, respectively) in a concentration-dependent manner in LVMs and LAMs. However, icariin had no significant effects on resting membrane potential (RMP) at concentrations of 5 and 10 μM (Figure [1B](#F1){ref-type="fig"}; Table [1](#T1){ref-type="table"}).

###### 

**Effects of icariin on action potentials (APs) in rabbit LVMs and LAMs**.

                **Ventricle (*****n*** = **14 cells/7 rabbits)**   **Atrium (*****n*** = **14 cells/6 rabbits)**                                                                                                                                     
  ------------- -------------------------------------------------- ----------------------------------------------- -------------------------------------------------------------------------- ---------- ------------------------------------------- ---------------------------------------------------------------------------
  RMP(mV)       −81 ± 2                                            −81 ± 3                                         −81 ± 5                                                                    −77 ± 3    −77 ± 4                                     −77 ± 6
  APA(mV)       114 ± 5                                            111 ± 6                                         108 ± 9[^\*^](#TN1){ref-type="table-fn"}                                   107 ± 7    104 ± 6                                     100 ± 5[^\*^](#TN1){ref-type="table-fn"}
  V~max~(V/s)   168 ± 10                                           146 ± 8[^\*^](#TN1){ref-type="table-fn"}        131 ± 6[^\*^](#TN1){ref-type="table-fn"}[^†^](#TN2){ref-type="table-fn"}   231 ± 10   222 ± 7                                     205 ± 13[^\*^](#TN1){ref-type="table-fn"}[^†^](#TN2){ref-type="table-fn"}
  APD~50~(ms)   158 ± 6                                            127 ± 5[^\*^](#TN1){ref-type="table-fn"}        107 ± 3[^\*^](#TN1){ref-type="table-fn"}[^†^](#TN2){ref-type="table-fn"}   103 ± 4    90 ± 9[^\*^](#TN1){ref-type="table-fn"}     72 ± 7[^\*^](#TN1){ref-type="table-fn"}[^†^](#TN2){ref-type="table-fn"}
  APD~90~(ms)   188 ± 4                                            157 ± 3[^\*^](#TN1){ref-type="table-fn"}        131 ± 4[^\*^](#TN1){ref-type="table-fn"}[^†^](#TN2){ref-type="table-fn"}   135 ± 8    122 ± 12[^\*^](#TN1){ref-type="table-fn"}   104 ± 11[^\*^](#TN1){ref-type="table-fn"}[^†^](#TN2){ref-type="table-fn"}

*RP, resting membrane potential; APA, action potential amplitude; V~max~, maximum upstroke velocity; APD~50~, action potential duration at 50% repolarization; APD~90~, action potential duration at 90% repolarization*.

p \< 0.05 vs. control;

*p \< 0.05 vs. 5 μM icariin*.

In our study, 5 and 10 μM icariin attenuated the rate-dependence (RD) of the APDs (*n* = 9 cells/4 rabbits; Figures [1C,D](#F1){ref-type="fig"}) in LVMs by 10.5 ± 4.3% and 28.5 ± 7.2% at a pacing cycle length (CL) of 500 ms, by 13 ± 4.9% and 32.2 ± 7.4% at a pacing CL of 1,000 ms and by 16.5 ± 4.8% and 34.5 ± 6.4% at a pacing CL of 2,000 ms, respectively.

Effects of icariin on cellular arrhythmias
------------------------------------------

In the present study, we used 10 nM anemonia toxin II (ATX-II) and a stimulation frequency of 0.25 Hz to elicit early afterdepolarizations (EADs) in LVMs. ATX-II significantly lengthened the APD from 179.78 ± 18.64 ms to 1186.44 ± 93.13 ms and induced EADs in 7 of 10 cells (70%; *n* = 10 cells/5 rabbits; Figures [2A--C](#F2){ref-type="fig"}), and 20 μM icariin decreased the APs prolonged by ATX-II from 1186.44 ± 93.13 ms to 360.08 ± 41.95 ms and completely abolished the EADs induced by ATX-II in seven cells. In another group, to elicit delayed afterdepolarizations (DADs) and triggered activities (TAs) in LVMs, we added 1 μM isoproterenol (ISO) to the external solution and the extracellular calcium concentration was elevated to 3.6 mM following a baseline pacing CL of 9,000 ms and on top of that 15 beats with a stimulation frequency of 2.5 Hz. DADs were noted in 6 of 9 cells (3 rabbits; 66.7%), and TAs were noted in 3 of 9 cells (33.3%). Administration of 10 μM icariin significantly suppressed the ISO-induced DADs and completely abolished the ISO-induced TAs (Figure [2D](#F2){ref-type="fig"}).

![**Effects of icariin on EADs and DADs, as well as TAs, in LVMs. (A,C)**. Administration of 20 μM Icariin completely abolished the EADs and attenuated the AP prolongations induced by 10 nM ATX-II at a stimulation frequency of 0.25 Hz. Single beats or 3 consecutive beats are displayed in **(A,C)**, respectively. **(B)** Summary data for APD~90~ after sequential administration of 10 nM ATX-II and 20 μM icariin. ^\*\*^*p* \< 0.01. **(D)**. DADs and TAs were induced in LVMs by a baseline pacing CL of 9,000 ms and on top of that 15 beats with a stimulation frequency of 2.5 Hz after superfusion with ISO (1 μM) and a high extracellular calcium concentration (\[Ca^2+^\]~o~, 3.6 mM). Administration of 10 μM icariin significantly suppressed the DADs and completely abolished the TAs induced by ISO and calcium.](fphys-08-00342-g0002){#F2}

Effects of icariin on I~NaT~ and I~NaL~
---------------------------------------

When the effects of icariin on I~NaT~ reached a steady state (3 min), the next concentration of the drug could be added to the external recording solution. Icariin (1, 5, 10, and 20 μM) reduced I~NaT~ in a dose-dependent manner in LVMs and LAMs. Figures [3A,B](#F3){ref-type="fig"} show the representative recordings for I~NaT~ in LVMs and LAMs, respectively, and Figure [3C](#F3){ref-type="fig"} shows the corresponding current-voltage relationships in LVMs and LAMs. The IC~50~ values for I~NaT~ in LVMs and LAMs were 11.83 ± 0.92 μM (*n* = 10 cells/6 rabbits) and 12.28 ± 0.29 μM (*n* = 8 cells/4 rabbits; *p* \> 0.05 LAMs vs. LVMs; Figure [3D](#F3){ref-type="fig"}), respectively. Figures [3E,G](#F3){ref-type="fig"} show typical current recordings, which were generated according to the steady-state inactivation protocol, in LVMs and LAMs. In the absence and presence of 20 μM icariin, the *V*~1/2~ values of the steady-state inactivation curves in LVMs were −85.47 ± 1.36 mV and −91.45 ± 1.48 mV (*n* = 8 cells/5 rabbits; *p* \< 0.01 vs. control), respectively, with corresponding *k*-values of 8.48 ± 1.05 and 8.28 ± 0.76 (*n* = 8 cells/5 rabbits; *p* \> 0.05 vs. control). Administration of 20 μM icariin shifted the *V*~1/2~ value of the steady-state inactivation curve in LAMs from −76.1 ± 1.52 mV to −82.28 ± 0.96 mV (*n* = 6 cells/3 rabbits; *p* \< 0.01 vs. control), with *k*-values of 8.29 ± 1.64 and 8.72 ± 0.81 (*n* = 6 cells/3 rabbits; *p* \> 0.05 vs. control). These results indicate that icariin induced a leftward (negative potential) shift of the steady-state inactivation curve of I~NaT~ in LVMs and LAMs (Figures [3F,H](#F3){ref-type="fig"}). However, it had no significant effects on the activation process in LVMs and LAMs (Figures [3F,H](#F3){ref-type="fig"}).

![**Effects of icariin on I~**NaT**~ in LVMs and LAMs. (A,B)**. Representative recordings of I~NaT~ in LVMs **(A)** and LAMs **(B)** after sequential applications of 5, 10, and 20 μM icariin. **(C)**. Current-voltage relationship of I~NaT~ in LVMs (left; *n* = 10 cells/6 rabbits) and LAMs (right; *n* = 13 cells/5 rabbits) in the absence and presence of icariin. ^\*^*p* \< 0.05 vs. control; ^φ^*p* \< 0.05 vs. 1 μM icariin; ^\#^*p* \< 0.05 vs. 5 μM icariin; ^϶^*p* \< 0.05 vs. 10 μM icariin. **(D)**. The dose-response relationships illustrating icariin-induced decreases in I~NaT~ in LVMs and LAMs. Data were fitted by the Hill equation. **(E**,**G)**. Representative current recordings of I~NaT~ elicited according to the steady-state inactivation protocol in LVMs **(E)** and LAMs **(G)** in the absence and presence of 20 μM icariin. (**(F)**. Steady-state activation (*n* = 8 cells/4 rabbits) and steady-state inactivation (*n* = 8 cells/5 rabbits) curves of I~NaT~ in LVMs before and after icariin administration. (**(H)**. Steady-state activation (*n* = 8 cells/4 rabbits) and steady-state inactivation (*n* = 6 cells/3 rabbits) curves of I~NaT~ in LAMs before and after icariin administration.](fphys-08-00342-g0003){#F3}

To identify I~NaL~, we recorded current before and after the application of 4 μM TTX using 300-ms depolarization pulses with potentials ranging from a HP of −90 mV to a potential of −20 mV. TTX (4 μM) had no significant effects on I~NaT~ but decreased the amplitude of I~NaL~ from −0.39 ± 0.004 pA/pF to 0.023 pA/pF (*n* = 6 cells/3 rabbits; *p* \< 0.01 vs. control), indicating that the TTX-sensitive current was I~NaL~. Administration of 10 nM ATX-II significantly enhanced I~NaL~, an effect that was reversed by administration of 1, 10, 20, and 40 μM icariin (*n* = 6 cells/4 rabbits; Figures [4A,C](#F4){ref-type="fig"}). The percentage inhibitions by 1, 10, 20, and 40 μM icariin of ATX-II augmented I~NaL~ were 7.8 ± 1%, 29 ± 6.4%, 43.68 ± 5.6%, and 61.4 ± 5.7%. Figure [4B](#F4){ref-type="fig"} shows the representative current recordings of I~NaL~ at −20 mV that are shown in Figure [4A](#F4){ref-type="fig"}.

![**Effects of icariin on ATX-II-induced increases in I~**NaL**~ in LVMs. (A)**. Representative current recordings of I~NaL~ in LVMs after sequential treatments with 10 nM ATX-II and 10, 20, and 40 μM icariin. (**B)**. Representative current recordings of I~NaL~ at −20 mV from **(A**,**C)**. The current-voltage relationship of I~NaL~ in LVMs, *n* = 6 cells/4 rabbits. ^\*^*p* \< 0.05 vs. control; ^\#^*p* \< 0.05 vs. 10 nM ATX-II; ^φ^*p* \< 0.05 vs. 1 μM icariin; ^϶^*p* \< 0.05 vs. 10 μM icariin; ^+^*p* \< 0.05 vs. 20 μM icariin.](fphys-08-00342-g0004){#F4}

Effects of icariin on I~CaL~
----------------------------

To elicit I~CaL~, we clamped LVMs at −40 mV and then depolarized the cells to +5 mV for 300 ms at 0.2 Hz. As shown in Figure [5A](#F5){ref-type="fig"}, the I~CaL~ run-down phenomenon lasted for approximately 5 min after membrane rupture in the control condition and then reached a steady state for 15 min (*n* = 5 cells/2 rabbits). I~CaL~ decreased by 8.5% during the this 5-min period. We performed a series of experiments on I~CaL~ during the stabilization period. To investigate the efficiency of the effects of icariin on I~CaL~ in LVMs, we recorded the current sequentially. As shown in Figure [5B](#F5){ref-type="fig"}, 10 μM icariin was added to the bath solution after the first (1st) current curve (control). I~CaL~ decreased rapidly between the tenth (10th) current curve (45 s after perfusion with icariin) and the thirteenth (13th) current curve (60 s after perfusion with icariin) and then decreased gradually until it reached a steady state (the twenty-seventh current curve). Icariin was washed out after 27th current curve (130 s after perfusion with icariin). I~CaL~ increased rapidly between the 27th current curve and the thirtieth (30th) current curve and then increased gradually until it reached its maximum value (82%) at the fifty-fifth current curve (270 s after perfusion with icariin). The summary data are shown in Figure [5C](#F5){ref-type="fig"} (*n* = 10 cells/4 rabbits). The above results indicate that icariin rapidly and reversibly inhibited I~CaL~ in LVMs.

![**Effects of icariin on I~**CaL**~ in LVMs and LAMs. (A)**. Time course of the I~CaL~ run-down phenomenon in LVMs under the control condition, *n* = 5 cells/2 rabbits. I~CaL~ were evoked by 300-ms depolarization pulses ranging from a holding potential of −40 mV to 5 mV at 0.2 Hz. **(B)**. Consecutive recordings of I~CaL~ evoked by a 300-ms depolarization from a holding potential of −40 mV to 5 mV at 0.2 Hz. The 1st sweep represents the control condition, the 2nd to 27th sweeps represent the period in which icariin exerted its effects on I~CaL~, and the 27th--55th sweeps indicate the period in which the effects of icariin on I~CaL~ were reversed. The inset represents the time course of the entire process, including the control condition, the icariin perfusion period, and the icariin wash-out period. The entire process was conducted during the stabilization period. (**(C)**. Summary data for the mean current densities of I~CaL~ in the control condition, the icariin perfusion period, and the icariin wash-out period, *n* = 10 cells/4 rabbits. ^\*^ and ^\*\*^*p* \< 0.05 and 0.01. **(D)**. Representative current recordings of I~CaL~ in LVMs after sequential applications of 1, 5, and 10 μM icariin. **(E)**. Representative current recordings of I~CaL~ in LAMs in the absence and presence of 5, 10, and 20 μM icariin. **(F)**. Current-voltage relationship of I~CaL~ in LVMs (left; *n* = 13 cells/6 rabbits) and LAMs (right; *n* = 9 cells/5 rabbits) before and after the application of icariin. ^\*^*p* \< 0.05 vs. control; ^∧^*p* \< 0.05 vs. 0.1 μM icariin; ^φ^*p* \< 0.05 vs. 1 μM icariin; ^\#^*p* \< 0.05 vs. 5 μM icariin; ^϶^*p* \< 0.05 vs. 10 μM icariin. **(G)**. The dose-response relationships illustrating icariin-induced decreases in I~CaL~ in LVMs and LAMs. ^\*^ and ^\*\*^ *p* \< 0.05 and *p* \< 0.01 LVMs vs. LAMs. Data were fitted by the Hill equation. **(H**,**J)**. Representative current recordings of I~CaL~evoked according to the steady-state inactivation protocol in LVMs **(H)** and LAMs **(J)** in the absence and presence of 10 μM icariin. **(I)**. Steady-state activation (*n* = 14 cells/7 rabbits) and steady-state inactivation (*n* = 10 cells/4 rabbits) curves of I~CaL~ in LVMs before and after icariin application. **(K)**. Steady-state activation (*n* = 12 cells/7 rabbits) and steady-state inactivation (*n* = 10 cells/6 rabbits) curves of I~CaL~ in LAMs before and after icariin application.](fphys-08-00342-g0005){#F5}

When the effects of icariin on I~CaL~ reached a steady state (2.5 min), the next concentration of the drug could be added to the bath solution. Figure [5D](#F5){ref-type="fig"} shows the representative I~CaL~ recordings in LVMs after sequential treatments of 0.1, 1, 5, 10 μM icariin and 1 μM nicardipine. Icariin decreased I~CaL~ in a concentration-dependent manner in LVMs, with an IC~50~ of 4.78 ± 0.89 μM (*n* = 8 cells/4 rabbits; Figure [5G](#F5){ref-type="fig"}). Nicardipine (1 μM) almost completely inhibited I~CaL~ in LVMs in the presence of 10 μM icariin, indicating that I~CaL~ was the nicardipine-sensitive current. Figure [5E](#F5){ref-type="fig"} shows the representative I~CaL~ recordings in LAMs after sequential treatments of 1, 5, 10, and 20 μM icariin. Icariin reduced I~CaL~ in a dose-dependent manner in LAMs, with an IC~50~ of 13.43 ± 2.73 μM (*n* = 9 cells/5 rabbits; *p* \< 0.01 vs. LVMs; Figure [5G](#F5){ref-type="fig"}). Figure [5F](#F5){ref-type="fig"} shows the I~CaL~ current-voltage relationships in LVMs (left, *n* = 13 cells/6 rabbits) and LAMs (right, *n* = 9 cells/5 rabbits). Icariin shifted the I~CaL~ steady-state inactivation curves to the left in LVMs and LAMs (Figures [5I,K](#F5){ref-type="fig"}). The *V*~1/2~ values before and after 10 μM icariin administration were shifted from −25.7 ± 1.01 mV and −29.96 ± 0.85 mV to −28.87 ± 2.18 mV (*n* = 10 cells/4 rabbits; *p* \< 0.01 vs. control; Figures [5H,I](#F5){ref-type="fig"}) and −33.94 ± 1.33 mV (*n* = 10 cells/6 rabbits; *p* \< 0.01 vs. control; Figures [5J,K](#F5){ref-type="fig"}), and the *k*-values were shifted from 7.16 ± 1.08 and 5.86 ± 0.82 to 7.52 ± 2.31 (*p* \> 0.05 vs. control) and 7.4 ± 1.14 (*p* \< 0.01 vs. control) in LVMs and LAMs, respectively. However, the drug has no significant effects on the activation process in these cells (Figures [5I,K](#F5){ref-type="fig"}).

Effects of icariin on main potassium currents
---------------------------------------------

To elicit I~K1~ in LVMs, we clamped the cells at −40 mV (to inactivate their sodium channels) and depolarized them from −120 mV to +50 mV in 5-mV increments for 400 ms at 0.5 Hz. As shown in Figures [6A,B](#F6){ref-type="fig"}, icariin (10 and 40 μM) had no effect on I~K1~ (*n* = 18 cells/8 rabbits). I~Kr~ in LVMs was elicited using a 3-s depolarization pulse whose potential was increased from a HP of −40 mV to a potential of 50 mV in 10-mV increments before returning to a potential of −40 mV for 5 s. Only the I~Kr~ tail-current (I~Kr−tail~) was measured. Icariin (10 and 40 μM) had no significant effects on I~Kr−tail~ (*n* = 12 cells/5 rabbits; Figures [6C,D](#F6){ref-type="fig"}). I~to~ in LAMs was elicited by 400 depolarization voltage steps with potentials that were increased from −80 mV to +50 mV in 10-mV increments, followed by a conditional test in which −40 mV was administered for 100 ms to block sodium currents. Forty micrometer icariin had no significant effect on I~*to*~in LAMs (*n* = 15 cells/6 rabbits; Figures [6E,F](#F6){ref-type="fig"}). I~Kur~ in LAMs was elicited by an 80-ms prepulse whose potential was increased from a HP of −50 mV to a potential of 30 mV (to inactivate I~to~), followed by 140-ms test pulses with potentials that were increased from −40 mV to +60 mV in 10-mV increments---using a HP of −50 mV---after a 50-ms interval before returning to −30 mV. Figure [6G](#F6){ref-type="fig"} shows the I~Kur~ current-voltage relationship in LAMs in the absence and presence of icariin (20 and 40 μM). Icariin had no significant effect on I~Kur~ (*n* = 1 5 cells/5 rabbits).

![**Effects of icariin on the main potassium current in LVMs and LAMs. (A)**. Representative current recordings of I~K1~ in LVMs before and after 40 μM icariin application. **(B)**. The current-voltage relationship of I~K1~ in LVMs in the absence and presence of icariin, *n* = 18 cells/8 rabbits. **(C)**. Representative current recordings of I~Kr~ in LVMs before and after 40 μM icariin application. **(D)**. The current-voltage relationship of I~Kr~ in LVMs in the absence and presence of icariin, *n* = 12 cells/5 rabbits. **(E)**. Representative current recordings of I~to~ in LAMs before and after 40 μM icariin application. **(F)**. The current-voltage relationship of I~to~ in LAMs in the absence and presence of icariin, *n* = 15 cells/6 rabbits. **(G)**. The current-voltage relationship of I~Kur~ in LAMs before and after icariin application (20 an 40 μM), *n* = 15 cells/5 rabbits.](fphys-08-00342-g0006){#F6}

Effects of icariin on aconitine-induced arrhythmias
---------------------------------------------------

In the NS group, VPC, VT, and VF were observed in all 10 rabbits. In the icariin group, VPC, VT and VF occurred in 9, 4 and 1 of 10 rabbits, respectively. Compared with the NS group, icariin application prior to aconitine administration increased the onset time (Figures [7A,B,D](#F7){ref-type="fig"}) and onset dosage (Figure [7C](#F7){ref-type="fig"}). The administration of icariin attenuated the incidence of arrhythmias induced by aconitine (Figure [7E](#F7){ref-type="fig"}) and rabbit mortality (Figure [7F](#F7){ref-type="fig"}).

![**Effects of icariin on aconitine-induced ventricular arrhythmias in whole rabbits. (A)**. Representative ECG recordings at different onset times of VPC (18 min), VT (23 min) and VF (54 min) in the NS group. **(B)**. Representative ECG recordings consistent with the times of events in **(A)** in the icariin group. **(C,D)**. Histograms show the onset dosage and onset time of aconitine-induced ventricular arrhythmias, respectively. ^\*\*^*p* \< 0.01. **(E)**. The incidence of VPC, VT, and VF induced by aconitine in the 2 groups. ^\*\*^*p* \< 0.01. **(F)**. Aconitine-induced mortality of rabbits in the 2 groups. ^\*\*^*p* \< 0.01. **(G)**. The onset time and onset dosage relationship of the 20 rabbits.](fphys-08-00342-g0007){#F7}

Discussion {#s4}
==========

The main findings of the present study are as follows: (I) icariin reduced APA and V~max~ of APs, shortened APDs (APD~50~and APD~90~) in LVMs and LAMs (Table [1](#T1){ref-type="table"}, Figure [1B](#F1){ref-type="fig"}). (II) Icariin decreased the RD of APD (Figures [1C,D](#F1){ref-type="fig"}) and significantly suppressed EADs and DADs and TAs induced by ATX-II or ISO and high \[Ca^2+^\]~o~, respectively, in LVMs (Figure [2](#F2){ref-type="fig"}). (III) Icariin decreased I~NaT~ in LVMs and LAMs (Figure [3](#F3){ref-type="fig"}) and attenuated the increases in I~NaL~ induced by ATX-II in a concentration dependent manner in LVMs (Figure [4](#F4){ref-type="fig"}). (IV) Icariin blocked I~CaL~ in a dose-dependent manner in LVMs and LAMs (Figure [5](#F5){ref-type="fig"}). Moreover, the inhibitory effects of icariin on I~CaL~ in LVMs were 2.8-fold stronger than those of icariin on the above current in LAMs. (V) Icariin had limited effects on I~K1~ and I~Kr~ in LVMs and on I~to~ and I~Kur~ in LAMs (Figure [6](#F6){ref-type="fig"}). (VI) Icariin inhibited aconitine-induced ventricular arrhythmias (Figure [7](#F7){ref-type="fig"}).

In this study, icariin decreased V~max~ of APs and shortened APDs (APD~50~ and APD~90~) in a concentration-dependent manner in LVMs and LAMs. The abovementioned decrease in APA and V~max~, which may be associated with the inhibitory effects of I~NaT~, can reduce conduction velocities, resulting in reentry blockade (Baba et al., [@B2]). Moreover, the APD shortening induced by icariin may be closely related to I~CaL~ inhibition because icariin does not affect I~K1~, I~Kr~, I~to~, and I~Kur~, which also play important roles in maintaining APD. Some drugs displays reverse rate dependence (RRD) of APD property, that is, the effect of a drug to prolong APD may be greater at slow than at fast heart rate, and vice versa. The findings of previous studies suggest that RRD of APD can be induced by enhancing I~CaL~ and inhibiting I~Kr~ or I~K1~(Bosch et al., [@B4]; Virag et al., [@B36]). RRD of APD enhancement leads to an increase in the cardiac transmural dispersion of the repolarization (Osadchii, [@B22]), which subsequently facilitates the occurrence of reentrant arrhythmias (Coronel et al., [@B6]; Maoz et al., [@B20]). In the present study, icariin attenuated I~CaL~ but had no effect on I~Kr~ or I~K1~, indicating that icariin might diminish or not produce RRD. These results suggest that icariin has increased antiarrhythmic efficiency compared with other drugs and that it is safer than its counterparts.

Sodium channels are known as the key targets of class I antiarrhythmic drugs. I~NaT~ is the main depolarization current in AP phase 0 and plays an important role in myocardial excitability and propagations (Goldin, [@B8]). In this study, icariin decreased the amplitude of I~NaT~, which caused a decrease in Na^+^ influx. Therefore, the results of this study indicate that icariin can relieve intracellular Na^+^ overload and exerts class I antiarrhythmic drug effects.

I~NaL~ is involved in the AP plateau phase (Kiyosue and Arita, [@B15]). A variety of pathological conditions, such as ischemia and hypoxia (Saint, [@B25]), cardiac hypertrophy and heart failure (Valdivia et al., [@B35]; Guo et al., [@B9]), can increase I~NaL~, resulting in an elevated intracellular sodium concentration (\[Na^+^\]~i~), as well as a subsequent increase in the intracellular Ca^2+^ concentration (\[Ca^2+^\]~i~) as a result of the activity of a reverse Na^+^/Ca^2+^ exchanger (NCX), leading to Ca^2+^ overload resulting in arrhythmia (Kihara and Morgan, [@B13]; Haigney et al., [@B10]; Yeh et al., [@B42]; Tang et al., [@B31]). On the other hand, increases in I~NaL~ can effectively lengthen the APD, resulting in EADs (Undrovinas et al., [@B33]). The authors of previous studies found that inhibiting I~NaL~ significantly prevented arrhythmias such as ventricular tachycardia and ventricular fibrillation (Pezhouman et al., [@B24]; Markandeya et al., [@B21]). Therefore, I~NaL~ is considered a new target for the treatment of arrhythmias (Undrovinas and Maltsev, [@B34]). In the present study, icariin reversed the increases in I~NaL~ induced by ATX-II (a known I~NaL~ opener), decreased I~CaL~, shortened the APD, and suppressed the EADs induced by ATX-II in LVMs. The percentage inhibitions by 1, 10, 20, and 40 μM icariin of ATX-II augmented I~NaL~ were 7.8 ± 1%, 29 ± 6.4%, 43.68 ± 5.6%, and 61.4 ± 5.7%. The percentage inhibitions by 3, 6, and 9 μM ranolazine of ATX II augmented I~NaL~ were 24 ± 6%, 44 ± 8%, and 62 ± 4% (Luo et al., [@B18]). The inhibitory effects of icariin on ATX-II augmented I~NaL~ is weaker than ranolazine (a known I~NaL~ blocker). Icariin can inhibit I~CaL~ and shorten APD, thus we concluded that icariin might inhibit ATX-II-induced arrhythmias by blocking I~NaL~ and I~CaL~.

I~CaL~ is one of the major inward currents in phase 2 of the AP and regulates Ca^2+^-related physiological processes (Benitah et al., [@B3]). Extracellular Ca^2+^ flows into cardiomyocytes mainly through L-type calcium channels and subsequently causes elevations in \[Ca^2+^\]~i~,which causes the sarcoplasmic reticulum to release large amounts of Ca^2+^ into the cytosol, a phenomenon known as Ca^2+^-induced Ca^2+^ release, which increases \[Ca^2+^\]~*i*~ further. A large number of studies have shown that various pathological conditions, including ischemia/reperfusion injury(de Diego et al., [@B7]) and heart failure (Casini et al., [@B5]), are associated with \[Ca^2+^\]~i~ abnormalities, especially intracellular Ca^2+^ overload, which plays a crucial role in the genesis of arrhythmias such as ventricular and atrial fibrillation (Kihara and Morgan, [@B13]; Yeh et al., [@B42]). Therefore, inhibiting I~CaL~ can facilitate \[Ca^2+^\]~*i*~reductions that suppress arrhythmias in the above pathological conditions. In this study, icariin decreased the amplitude of I~CaL~, which caused a decrease in Ca^2+^ influx. Therefore, icariin exerts class IV antiarrhythmic drug effects by inhibiting I~CaL~. DADs and TAs can be induced by \[Ca^2+^\]~i~ overload caused by the application of ISO and high \[Ca^2+^\]~o~ (Shutt et al., [@B26]; Sicouri et al., [@B27]). In the present study, icariin significantly suppressed DADs and TAs in LVMs, possibly by inhibiting I~CaL~. Moreover, the inhibition of I~CaL~ induced by icariin in LVMs was 2.8-fold stronger than that induced by icariin in LAMs. Thus, icariin shows a degree of ventricular selectivity with respect to its inhibitory effects on I~CaL~.

Elevations in \[Ca^2+^\]~i~ increase I~NaL~ by activating the CAMK II and PKC pathways (Ma et al., [@B19]; Wu et al., [@B40]). The increased I~NaL~ elevates \[Na^+^\]~i~, which increases \[Ca^2+^\]~i~ by activating a reverse NCX (Kihara and Morgan, [@B13]; Haigney et al., [@B10]; Yeh et al., [@B42]; Tang et al., [@B31]). The cellular response may cause or aggravate arrhythmias. In the present study, icariin inhibited both sodium currents (I~NaT~ and I~NaL~) and I~CaL~, which blocked the cellular response more effectively, indicating that icariin may be a more effective antiarrhythmic drug than established medications.

I~Kr~ is an important outward current in AP repolarization. Decreases in I~Kr~ lengthen the APD and lead to QT interval prolongation. A variety of noncardiovascular drugs can block I~Kr~, thereby inducing long QT syndrome and torsade de pointes (TdPs) (Viskin et al., [@B37]). For example, grepafloxacin, a quinolone antibiotic, was withdrawn from the American drug market because it blocked I~Kr~ significantly and caused excessive QT interval prolongation, resulting in TdPs (Anderson et al., [@B1]). Therefore, the authors of another study measured I~Kr~ antagonist potency to evaluate the proarrhythmic effects of new drugs (Kim et al., [@B14]) and found that it did not affect I~Kr~. In this study, icariin showed no effect on I~Kr~. Thus, we deemed the compound a safer drug than its established counterparts.

Aconitine, a specific sodium channel agonist, sustained activation of the sodium channels and induced intracellular Na^+^ accumulation leading to intracellular Ca^2+^ overload through NCX (Peper and Trautwein, [@B23]). Moreover, icariin can augment I~CaL~ directly causing intracellular Ca^2+^ overload, which may eventually result in arrhythmias (Zhou et al., [@B45]). In the present study, we found that icariin increased the onset time and onset dosage of aconitine-induced VPC, VT and VF in whole rabbits. It also decreased the incidence of aconitine-induced VT and VF, as well as mortality in rabbits. The above results indicate that icariin shows cardioprotective effects against aconitine-induced arrhythmias. The cardioprotective effects may be due to reduction of I~NaT~, I~NaL~ and I~CaL~.

Conclusion {#s5}
==========

In summary, we found for the first time that icariin exerted class I and IV antiarrhythmic agent effects and moderately inhibited I~NaL~. Icariin inhibits aconitine-induced arrhythmias in whole rabbits. Icariin also suppressed EADs or DADs and TAs induced by ATX-II or ISO and high \[Ca^2+^\]~o~, respectively, by inhibiting I~NaT~, I~NaL~, and I~CaL~, but had no effect on I~K1~, I~Kr~, I~*to*~, and I~Kur~, especially I~Kr~, which may indicate that icariin is a safer drug than its counterparts. Thus, icariin may have promise as an agent used in the clinical treatment of arrhythmia.
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AP

:   action potential

LAM

:   left atrial myocyte

LVM

:   left ventricular myocyte

APD

:   action potential duration

APD~50~ and APD~90~

:   APD at 50 and 90% repolarization

V~max~

:   maximum upstroke velocity of AP

APA

:   AP amplitude

RMP

:   resting membrane potential

RD

:   rate dependence of the APD

RRD

:   reverse rate dependence of the APD

ATX-II

:   anemonia toxin II

EAD

:   early afterdepolarization

DAD

:   delayed afterdepolarization

TA

:   triggered activity

ISO

:   isoproterenol

\[Ca^2+^\]~o~

:   extracellular calcium concentration

I~NaT~

:   transient sodium current

I~CaL~

:   L-type calcium current

I~NaL~

:   late sodium current

I~K1~

:   inward rectifier potassium current

I~Kr~

:   rapid component of delayed rectifier potassium current

I~to~

:   transient outward potassium current

I~Kur~

:   ultra-rapid delayed rectifier potassium current

CL

:   cycle length

(VPC)

:   ventricular premature contraction

(VT)

:   ventricular tachycardia

(VF)

:   ventricular fibrillation
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